The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Akero Therapeutics shares traded near their all-time high as the drugmaker reported positive results in a study of its treatment for liver disease.

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

Stocks were sharply lower Monday afternoon on concerns about the competitive threat that China poses in the race to develop artificial intelligence.

A Chinese start-up’s new artificial intelligence program took the top spot in Apple’s app store, threatening U.S. dominance ...

Last week's ICR Conference in Orlando shed light on how tech and AI are making inroads into improving restaurant experiences and increasing efficiency among quick-service eating establishments.